AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) was upgraded by BidaskClub from a “buy” rating to a “strong-buy” rating in a research report issued on Wednesday.

Several other analysts have also issued reports on the stock. Piper Jaffray Companies restated a “buy” rating and set a $3.50 price target on shares of AVEO Pharmaceuticals in a research report on Thursday, August 10th. Zacks Investment Research upgraded shares of AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a report on Monday, July 24th. FBR & Co reiterated an “outperform” rating and set a $3.00 target price on shares of AVEO Pharmaceuticals in a report on Thursday, July 13th. Finally, ValuEngine upgraded shares of AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, June 24th. One equities research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $3.08.

Shares of AVEO Pharmaceuticals (NASDAQ AVEO) traded up 2.1283% on Wednesday, reaching $3.1047. The company’s stock had a trading volume of 1,241,467 shares. The firm’s market cap is $342.64 million. The stock has a 50 day moving average of $2.58 and a 200-day moving average of $1.19. AVEO Pharmaceuticals has a 12 month low of $0.50 and a 12 month high of $3.30. AVEO Pharmaceuticals also was the target of some unusual options trading activity on Monday. Traders purchased 7,601 put options on the stock. This represents an increase of 1,385% compared to the average daily volume of 512 put options.

WARNING: “AVEO Pharmaceuticals, Inc. (AVEO) Upgraded by BidaskClub to Strong-Buy” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/aveo-pharmaceuticals-inc-aveo-upgraded-by-bidaskclub-to-strong-buy/1494859.html.

Institutional investors have recently added to or reduced their stakes in the company. Fore Research & Management LP bought a new position in AVEO Pharmaceuticals during the second quarter worth about $111,000. Clear Harbor Asset Management LLC acquired a new position in shares of AVEO Pharmaceuticals during the second quarter worth $289,000. Cannell Peter B & Co. Inc. increased its position in shares of AVEO Pharmaceuticals by 22.9% in the second quarter. Cannell Peter B & Co. Inc. now owns 109,875 shares of the biopharmaceutical company’s stock worth $244,000 after buying an additional 20,500 shares in the last quarter. Paloma Partners Management Co acquired a new position in shares of AVEO Pharmaceuticals during the first quarter worth $184,000. Finally, UBS Oconnor LLC acquired a new position in shares of AVEO Pharmaceuticals during the first quarter worth $291,000. 51.03% of the stock is owned by institutional investors.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.